HHS announces new funding opportunities for psychedelics, with focus on ibogaine
Alcoholism & Drug Abuse Weekly · 23.11.2026 · 38 (45) · 4-6
DOI: 10.1002/adaw.35123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alcoholism & Drug Abuse Weekly, online erschienen am 20.11.2026. Verfasst von Alison Knopf.
Abstract (Originalsprache)
Last week, the Department of Health and Human Services (HHS) announced two new investments to promote the development of psychedelics to treat mental illness. First, the National Institute of Mental Health (NIMH) published a $20 million notice of funding opportunity to support the development of a research network to study rapid‐acting psychotropic interventional drugs such as ketamine, esketamine, psilocybin and other emerging treatments for serious mental illnesses. Second, investments up to $4.9 million through the Advanced Research Projects Agency for Health (ARPA‐H) were announced to advance the development of ibogaine as a potential treatment for post‐traumatic stress disorder (PTSD) and other serious mental illnesses.
Zitieren
APA
Knopf, A. (2026). HHS announces new funding opportunities for psychedelics, with focus on ibogaine. Alcoholism & Drug Abuse Weekly, 38(45), 4-6. https://doi.org/10.1002/adaw.35123
Vancouver
Knopf A. HHS announces new funding opportunities for psychedelics, with focus on ibogaine. Alcoholism & Drug Abuse Weekly. 2026;38(45):4-6. doi:10.1002/adaw.35123
BibTeX
@article{Knopf2026,
author = {Knopf, Alison},
title = {HHS announces new funding opportunities for psychedelics, with focus on ibogaine},
journal = {Alcoholism & Drug Abuse Weekly},
year = {2026},
volume = {38},
number = {45},
pages = {4--6},
doi = {10.1002/adaw.35123}
}
EUVIMED